One 79-year-old man is taking retatrutide, Eli Lilly's most powerful experimental obesity drug. Roughly 100 million American adults have obesity and cannot get it. The gap between those two numbers is the whole story, and a group of bioethicists thinks the way it was bridged does not add up.
According to STAT News ↗, which broke the case on June 23, the FDA cleared a single-patient "compassionate use" request for the man in April. The request came from Dr. Ranganath Muniyappa at the National Institute of Diabetes and Digestive and Kidney Diseases, part of the NIH. The patient had refractory obesity along with obstructive sleep apnea and severe pulmonary hypertension, which is abnormally high blood pressure in the vessels of the lungs. He had spent a year on tirzepatide, the drug sold as Mounjaro and Zepbound, with only moderate results before the retatrutide request went in.
Compassionate use, also called expanded access, is a real and well-worn pathway. It lets a patient with a serious or life-threatening condition and no good remaining options take a drug that has not been approved yet, outside of a clinical trial. The bar is usually high. The drug is usually for a disease that is killing the patient now, not one managed over years.
That is the part the experts flagged. STAT spoke with 18 bioethicists, obesity-medicine clinicians, and current and former government health officials, and the application "struck them as unusual." Their problem was not that one sick man got a drug. It was the shape of the decision. Obesity is not a rare disease. When a condition affects tens of millions of people, the standard tools for broadening access before approval are treatment protocols built for groups, not a one-person exception. And the standard route to retatrutide specifically is the trial: Lilly is still enrolling its TRIUMPH program, including studies in obesity, diabetes, and sleep apnea.
Alison Bateman-House, a medical ethicist at NYU, put the question plainly to the Boston Globe ↗: if the goal was treating obesity in people who cannot use what is already on the market, "why would you go the single patient route?" Jamy Ard, an obesity physician, said he had never heard of an obesity-drug company offering compassionate use at all. Richard Klein, a former FDA expanded-access official, noted that Lilly's program posting on the federal trials registry left out the qualifying conditions and eligibility details that such postings normally carry. "Only people in the know would be able to find this," he said.
Lilly has not explained how it evaluates these requests. A company spokesperson, Misty Fuller, told reporters only that "we make these decisions following all applicable regulations" and declined to discuss specifics.
The case has a political layer too. The patient's age, the timing, and the NIH connection have fed speculation about who he is, and on June 25 Senator Maggie Hassan sent a formal letter ↗ to Health and Human Services Secretary Robert F. Kennedy Jr. asking whether the recipient is President Trump. The identity question will get the cable-news oxygen. The access question is the one that outlasts it.
That is where the molecule matters. Retatrutide is a triple agonist: a single peptide engineered to hit three gut-hormone receptors at once, the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Hitting all three is what makes it the most aggressive weight-loss agent Lilly has put into late-stage trials, and Lilly has said it plans to file for approval later in 2026. Until that happens, the drug exists in a narrow window where it is good enough that a federal scientist filed paperwork to get one patient on it, and unapproved enough that everyone else has to wait for the trial or the label. A compassionate-use program is supposed to be the pressure valve for that window. The bioethicists are asking whether it was used as one, or as a side door.